All In Biotech

Drug Trial Radar · NCT05174169

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,912 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,912

Planned (sponsor's estimate)

Start

Jul 8, 2022

Primary completion

Mar 10, 2029

Study completion Mar 10, 2030

Sponsor

Lead sponsor
NRG OncologyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Natera, Inc.; National Cancer Institute (NCI)
First posted
Dec 30, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.

Conditions

  • Stage III Colon Cancer

Interventions

  • Signatera testDevice

    Central ctDNA testing for all patients

  • mFOLFOX6 3-6 monthDrug

    Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + 5-Fluorouracil (5-FU) 400mg/m2 bolus + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 6-12 cycles

  • CAPOX 3 monthDrug

    Oxaliplatin 130 mg/m2 IV Day 1 every 3 weeks + Capecitabine 1000 mg/m2 BID by mouth days 1-14 every 3 weeks for 4 cycles

  • mFOLFIRINOXDrug

    Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + Irinotecan 150 mg/m2 IV continuous infusion (30-90 minutes) + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 12 cycles

  • mFOLFOX6 6 monthDrug

    Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + 5-Fluorouracil (5-FU) 400mg/m2 bolus + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 12 cycles

  • CAPOX 6 monthDrug

    Oxaliplatin 130 mg/m2 IV Day 1 every 3 weeks + Capecitabine 1000 mg/m2 BID by mouth days 1-14 every 3 weeks for 8 cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ctDNA positive status (TTPos)Time frame: Time from randomization to the first TTPos event, a maximum of 3 years
  2. Disease-Free Survival (DFS)Time frame: Time from randomization to disease-free survival event, a maximum of 5 years]

Locations

1,085 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama · Active not recruiting

  • Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis

    Daphne, Alabama · Suspended

  • Thomas Hospital

    Fairhope, Alabama · Suspended

  • Mobile Infirmary Medical Center

    Mobile, Alabama · Suspended

  • University of South Alabama Mitchell Cancer Institute

    Mobile, Alabama · Recruiting

  • Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland

    Saraland, Alabama · Suspended

  • Kingman Regional Medical Center

    Kingman, Arizona · Recruiting

  • Cancer Center at Saint Joseph's

    Phoenix, Arizona · Recruiting

  • Mayo Clinic Hospital in Arizona

    Phoenix, Arizona · Active not recruiting

  • Banner University Medical Center - Tucson

    Tucson, Arizona · Recruiting

  • University of Arizona Cancer Center-North Campus

    Tucson, Arizona · Recruiting

  • Mercy Hospital Fort Smith

    Fort Smith, Arkansas · Recruiting

  • CHI Saint Vincent Cancer Center Hot Springs

    Hot Springs, Arkansas · Suspended

  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro

    Jonesboro, Arkansas · Recruiting

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas · Recruiting

  • Kaiser Permanente-Anaheim

    Anaheim, California · Recruiting

  • Kaiser Permanente-Deer Valley Medical Center

    Antioch, California · Recruiting

  • Mission Hope Medical Oncology - Arroyo Grande

    Arroyo Grande, California · Recruiting

  • PCR Oncology

    Arroyo Grande, California · Recruiting

  • Sutter Auburn Faith Hospital

    Auburn, California · Recruiting

  • Sutter Cancer Centers Radiation Oncology Services-Auburn

    Auburn, California · Recruiting

  • AIS Cancer Center at San Joaquin Community Hospital

    Bakersfield, California · Recruiting

  • Kaiser Permanente-Baldwin Park

    Baldwin Park, California · Recruiting

  • Kaiser Permanente-Bellflower

    Bellflower, California · Recruiting

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California · Recruiting

  • Tower Cancer Research Foundation

    Beverly Hills, California · Recruiting

  • Mills-Peninsula Medical Center

    Burlingame, California · Recruiting

  • Marshall Cancer Center

    Cameron Park, California · Recruiting

  • Sutter Cancer Centers Radiation Oncology Services-Cameron Park

    Cameron Park, California · Recruiting

  • Mercy Cancer Center - Carmichael

    Carmichael, California · Recruiting

  • Mercy San Juan Medical Center

    Carmichael, California · Recruiting

  • Eden Hospital Medical Center

    Castro Valley, California · Recruiting

  • Enloe Medical Center

    Chico, California · Recruiting

  • Sutter Davis Hospital

    Davis, California · Recruiting

  • City of Hope Comprehensive Cancer Center

    Duarte, California · Recruiting

  • Epic Care-Dublin

    Dublin, California · Suspended

  • Kaiser Permanente Dublin

    Dublin, California · Recruiting

  • Mercy Cancer Center - Elk Grove

    Elk Grove, California · Recruiting

  • Epic Care Partners in Cancer Care

    Emeryville, California · Suspended

  • Kaiser Permanente-Fontana

    Fontana, California · Recruiting

Showing 40 of 1,085 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.